Form 4: ACMR CEO David Wang Sells Shares Under 10b5-1 Plan

ACM Research CEO David H. Wang executed pre-planned sales of Class A Common Stock totaling 130,000 shares in early September 2025, following option exercises.

Summary

• David H. Wang, CEO, President, Director, and 10% Owner of ACM Research, Inc. (ACMR), reported transactions involving Class A Common Stock.
• On September 3, 2025, Wang acquired 70,000 shares of Class A Common Stock through option exercise at a price of $1.00 per share.
• Also on September 3, 2025, Wang disposed of 66,057 shares at a weighted average price of $26.73 (ranging from $26.25 to $27.19) and 3,943 shares at a weighted average price of $27.31 (ranging from $27.29 to $27.33).
• On September 4, 2025, Wang acquired 60,000 shares of Class A Common Stock through option exercise at a price of $1.00 per share.
• Also on September 4, 2025, Wang disposed of 60,000 shares at a weighted average price of $26.44 (ranging from $26.14 to $26.68).
• All sales were executed pursuant to a Rule 10b5-1 trading plan adopted on November 29, 2024.
• Following these transactions, Wang's direct beneficial ownership of Class A Common Stock decreased to 672,708 shares.
• Indirect beneficial ownership includes 100,002 shares by Jing Chen (wife), 45,837 shares by Sophia Wang (daughter), 180,000 shares by David Hui Wang and Jing Chen Family Irrevocable Trust for Wang Children, and 620,001 shares by Wang-Chen Family Living Trust.
• Remaining derivative securities (stock options) beneficially owned after transactions total 740,002, with an exercise price of $1.00 and an expiration date of December 27, 2026.

Sentiment

Score: 5

Explanation: The transactions represent pre-planned insider sales under a Rule 10b5-1 plan, which are generally viewed as neutral events rather than a signal of management's view on future performance. The sales are a result of option exercises, indicating a monetization of vested equity.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled liquidation rather than a reaction to new, negative material information.
• Options were exercised at a low price of $1.00, demonstrating a significant in-the-money position for the reporting person.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors, potentially signaling a lack of confidence, although the 10b5-1 plan mitigates this concern.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2024.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions and does not provide specific information about broader industry trends or competitive landscape. ACM Research operates in the semiconductor equipment industry.

Stakeholder Impact

• Shareholders may interpret insider sales, even if pre-planned, with varying degrees of concern, though the 10b5-1 plan typically mitigates the perception of negative sentiment from management.

Key Dates

Recommendation

The insider sales by CEO David H. Wang were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled liquidation rather than a reaction to new material information. While insider selling can sometimes be a negative signal, the pre-planned nature mitigates this concern, suggesting a neutral impact on the company's fundamental outlook. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

ACM Research, ACMR, David H. Wang, Insider Trading, Form 4, Stock Sale, Option Exercise, 10b5-1 Plan, Semiconductor Equipment